|The full article is available to subscribers||Subscriber Login|
The FDA has approved nusinersen (Spinraza – Biogen) for treatment of spinal muscular atrophy (SMA), a hereditary neurodegenerative disease that occurs in about one in every 10,000 births.1 It is the first drug to be approved in the US for this indication.
SPINAL MUSCULAR ATROPHY — SMA is an autosomal recessive neuromuscular disorder in which degeneration of alpha motor neurons in the anterior horn cells of the spinal cord leads to muscle weakness and atrophy. Most cases are caused by a homozygous deletion or mutation in the 5q13 survival of motor neuron 1 (SMN1) gene, which leads to SMN protein deficiency. Mutations in a similar gene, SMN2, are correlated with a milder SMA phenotype.2
SMA is classified based on the age of symptom onset and motor function achieved. Infants with type 1 SMA (age of onset 0-6 months) are unable... more
- TW Prior et al. Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A 2010; 152A:1608.
- MA Farrar et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol 2016 Dec 27 (epub).
- SJ Kolb and JT Kissel. Spinal muscular atrophy. Neurol Clin 2015; 33: 831.
- RS Finkel et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 2016; 388:3017.
- CA Chiriboga et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology 2016; 86:890.
- M Haché et al. Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience. J Child Neurol 2016; 31:899.
- WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. March 5, 2017. Reprinted with permission by First Databank, Inc. All rights reserved. ©2017. www.fdbhealth.com/policies/drug-pricing-policy.